Literature DB >> 19967371

Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization.

Ahsun Riaz1, Robert J Lewandowski, Laura Kulik, Robert K Ryu, Mary F Mulcahy, Talia Baker, Vanessa Gates, Ritu Nayar, Ed Wang, Frank H Miller, Kent T Sato, Reed A Omary, Michael Abecassis, Riad Salem.   

Abstract

To correlate posttreatment radiologic and pathologic findings in patients who underwent transarterial chemoembolization before transplantation or resection. Thirty-five patients with postchemoembolization follow-up imaging underwent liver transplantation/resection. Pre- and posttreatment contrast-enhanced magnetic resonance imaging were used to evaluate radiologic findings. Imaging characteristics using World Health Organization (WHO) and European Association for the Study of the Liver (EASL) criteria after treatment were evaluated. Treated lesions were examined by pathology (gold standard) for the assessment of necrosis. Radiologic findings on magnetic resonance imaging were correlated to pathologic findings to assess the predictability by imaging of actual necrosis. Kappa (κ) statistics were used to determine intermethod agreement between WHO and EASL criteria. Fourteen (40%) of 35 lesions had biopsy-proven hepatocellular carcinoma. Thirteen (37%) of 35 target lesions showed complete pathologic necrosis. Complete pathologic necrosis was seen in 35% of lesions with pretreatment size <3 cm. Complete pathologic necrosis was seen in 1 (100%) of 1, 6 (67%) of 9, 6 (33%) of 18, and 0 (0%) of 7 of the lesions that exhibited complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) by WHO criteria, respectively. Complete pathologic necrosis was seen in 9 (82%) of 11, 4 (36%) of 11, 0 (0%) of 8, and 0 (0%) of 5 of the lesions that showed CR, PR, SD, or PD by EASL criteria, respectively. EASL CR and WHO response were shown to have ≥85% specificity for predicting complete pathologic necrosis. The κ coefficient for agreement between WHO and EASL was 0.29. EASL and WHO criteria had minimal intermethod agreement. EASL CR and WHO response were able to predict pathologic necrosis.

Entities:  

Mesh:

Year:  2009        PMID: 19967371      PMCID: PMC2921465          DOI: 10.1007/s00270-009-9766-5

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  30 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis.

Authors:  J F Geschwind; D Artemov; S Abraham; D Omdal; M S Huncharek; C McGee; A Arepally; D Lambert; A C Venbrux; G B Lund
Journal:  J Vasc Interv Radiol       Date:  2000 Nov-Dec       Impact factor: 3.464

3.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

4.  Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma.

Authors:  Ihab R Kamel; David A Bluemke; Douglas Ramsey; Mohammad Abusedera; Michael Torbenson; John Eng; Gilberto Szarf; Jean-Francois Geschwind
Journal:  AJR Am J Roentgenol       Date:  2003-09       Impact factor: 3.959

Review 5.  Hepatocellular carcinoma and hepatitis C in the United States.

Authors:  Hashem B El-Serag
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 6.  Chemoembolization for hepatocellular carcinoma.

Authors:  Jordi Bruix; Margarita Sala; Josep M Llovet
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors:  Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

8.  Extrahepatic metastases of hepatocellular carcinoma.

Authors:  S Katyal; J H Oliver; M S Peterson; J V Ferris; B S Carr; R L Baron
Journal:  Radiology       Date:  2000-09       Impact factor: 11.105

9.  Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization.

Authors:  Yamini K Maddala; Linda Stadheim; James C Andrews; Lawrence J Burgart; Charles B Rosen; Walter K Kremers; Gregory Gores
Journal:  Liver Transpl       Date:  2004-03       Impact factor: 5.799

Review 10.  The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.

Authors:  Josep M Llovet; Josep Fuster; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

View more
  28 in total

1.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.

Authors:  Riad Salem; Robert J Lewandowski; Laura Kulik; Edward Wang; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Saad M Ibrahim; Seanthan Senthilnathan; Talia Baker; Vanessa L Gates; Bassel Atassi; Steven Newman; Khairuddin Memon; Richard Chen; Robert L Vogelzang; Albert A Nemcek; Scott A Resnick; Howard B Chrisman; James Carr; Reed A Omary; Michael Abecassis; Al B Benson; Mary F Mulcahy
Journal:  Gastroenterology       Date:  2010-10-30       Impact factor: 22.682

2.  Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis.

Authors:  Julius Chapiro; Laura D Wood; MingDe Lin; Rafael Duran; Toby Cornish; David Lesage; Vivek Charu; Rüdiger Schernthaner; Zhijun Wang; Vania Tacher; Lynn Jeanette Savic; Ihab R Kamel; Jean-François Geschwind
Journal:  Radiology       Date:  2014-07-15       Impact factor: 11.105

3.  Value of the portal venous phase in evaluation of treated hepatocellular carcinoma following transcatheter arterial chemoembolisation.

Authors:  A Lam; D Fernando; C C Sirlin; M Nayyar; S C Goodwin; D K Imagawa; C Lall
Journal:  Clin Radiol       Date:  2017-08-02       Impact factor: 2.350

4.  Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.

Authors:  Khairuddin Memon; Laura Kulik; Robert J Lewandowski; Edward Wang; Robert K Ryu; Ahsun Riaz; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Talia Baker; Michael Abecassis; Al B Benson; Mary F Mulcahy; Reed A Omary; Riad Salem
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

5.  Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation.

Authors:  Sharon W Kwan; Nicholas Fidelman; Elizabeth Ma; Robert K Kerlan; Francis Y Yao
Journal:  Liver Transpl       Date:  2012-06       Impact factor: 5.799

6.  Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma.

Authors:  Dingxin Wang; Ron C Gaba; Brian Jin; Ahsun Riaz; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Ann B Ragin; Laura M Kulik; Mary F Mulcahy; Riad Salem; Andrew C Larson; Reed A Omary
Journal:  Acad Radiol       Date:  2011-07       Impact factor: 3.173

7.  Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.

Authors:  Khairuddin Memon; Laura Kulik; Robert J Lewandowski; Edward Wang; Ahsun Riaz; Robert K Ryu; Kent T Sato; Karen Marshall; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Seanthan Senthilnathan; Talia Baker; Vanessa L Gates; Michael Abecassis; Al B Benson; Mary F Mulcahy; Reed A Omary; Riad Salem
Journal:  Gastroenterology       Date:  2011-04-30       Impact factor: 22.682

8.  Evaluation of the Heat Sink Effect After Transarterial Embolization When Performed in Combination with Thermal Ablation of the Liver in a Rabbit Model.

Authors:  Charles J Puza; Qi Wang; Charles Y Kim
Journal:  Cardiovasc Intervent Radiol       Date:  2018-07-23       Impact factor: 2.740

Review 9.  Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives.

Authors:  Cristina Mosconi; Alberta Cappelli; Cinzia Pettinato; Rita Golfieri
Journal:  World J Hepatol       Date:  2015-04-18

10.  Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.

Authors:  Michael Vouche; Laura Kulik; Rohi Atassi; Khairuddin Memon; Ryan Hickey; Daniel Ganger; Frank H Miller; Vahid Yaghmai; Michael Abecassis; Talia Baker; Mary Mulcahy; Ritu Nayar; Robert J Lewandowski; Riad Salem
Journal:  Hepatology       Date:  2013-10-01       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.